Perhaps more would be willing to do adjuvant Herceptin for very early stage disease and or late Herceptin if they knew that the response rate would be pushing near 70-75%.
According to the link below, 20% of the Her2+ node negative early stage breast cancers have p95 form of the receptor. As we know, p95 is truncated without the cleavated extracellular membrane for herceptin to fit into. Perhaps we can logically conclude that these 20% therefore would not respond to Herceptin. Conversely, we could conclude that if you have p185, then your response would be increased some 20% since you don't have p95.Accordingly, then you could conclude that your response rate to adjuvant Herceptin may be as high as 70%.
Okay, now here comes the big question, why aren't onclogist testing for these two forms of the receptors when these tests are available via of Western Blot and Tab250? I guess they are awaiting for in vivo study, human, to varify it all. But come on,the writing is on the wall, let's hurry HERA trial with those specimen analyses!!!!!!!!!!!!!!!!!
http://clincancerres.aacrjournals.o...nt/full/8/2/347
__________________
Fondly,
Robin
Threaded Mode